^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    1d
    COMPARE: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, Charite University, Berlin, Germany | Not yet recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Mar 2027 --> Jun 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab)
    1d
    A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, Juventas Cell Therapy Ltd. | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120
    2d
    ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov)
    P1/2, N=160, Active, not recruiting, Allogene Therapeutics | Trial primary completion date: Aug 2025 --> Feb 2029
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • fludarabine IV • cemacabtagene ansegedleucel (ALLO-501A) • ALLO-647
    2d
    An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report. (PubMed, Front Immunol)
    We report a 63-year-old male patient with diffuse large B-cell lymphoma (DLBCL) who developed delayed-onset neurotoxicity on day +22 following CD19-directed CAR T-cell therapy with axicabtagene ciloleucel (axi-cel), after an initial episode of CRS and ICANS...Follow-up neuropsychological testing revealed persistent deficits in attention and processing speed. This case broadens the known neurotoxicity spectrum of CAR T-cell therapies and underscores the need for heightened clinical vigilance and refined diagnostic criteria beyond ICANS, even in CD19-targeted settings.
    Journal • Adverse events
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • NEFL (Neurofilament Light Chain)
    |
    Yescarta (axicabtagene ciloleucel)
    4d
    Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jul 2026 --> Dec 2027 | Initiation date: Sep 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV
    4d
    A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=16, Recruiting, Chulalongkorn University | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    IL7R (Interleukin 7 Receptor)
    |
    CD19 positive
    4d
    Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    5d
    CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Stanford University
    New P1 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC rearrangement + BCL2 rearrangement
    |
    rapcabtagene autoleucel (YTB323)
    5d
    A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P1, N=7, Completed, China Immunotech (Beijing) Biotechnology Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026
    Trial completion • Trial completion date